Results 111 to 120 of about 3,650 (207)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate. [PDF]

Contracept X, 2022
Taylor DJ, Halpern V, Brache V, Bahamondes L, Jensen JT, Dorflinger LJ.   +5 more
europepmc   +1 more source

Green Tea Extract has a Protective Effect on Leptin and Lipid Profile Levels Due to the Induction of Depot Medroxyprogesterone Acetate. [PDF]

Med Arch, 2023
Wahyuni ES, Maryatun M, Veri N, Susilawati E, Firrahmawati L, Wahyuni ES, Wulandari R.   +6 more
europepmc   +1 more source

Depot medroxyprogesterone acetate (Depo-Provera) as a contraceptive preparation.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1971
Experience with depot medroxyprogesterone acetate as a contraceptive preparation in 7 335 patients for a total of 38 714 months over a 3-year period is described. The discontinuation rate was 18.3% and the failure rate 0-35 per 100 women-years of use. This compares very well with all other methods of contraception.
openaire   +2 more sources

Vagino-Laparoscopic Conservative Strategy of Hysterectomy in Indicated Cases of Severe Pelvic Endometriosis Followed by 24 Months of Depot-Medroxyprogesterone Acetate Therapy- A Symptom-Solving Treatment Model to Ease Surgical Challenges. [PDF]

Int J Womens Health, 2023
Purohit R, Sharma JG, Meher D, Samy MM.
europepmc   +1 more source

New contraceptive eligibility checklists for provision of combined oral contraceptives and depot-medroxyprogesterone acetate in community-based programmes

Bulletin of the World Health Organization, 2000
Community-based services (CBS) have long used checklists to determine eligibility for contraceptive method use, in particular for combined oral contraceptives (COCs) and the 3-month injectable contraceptive depot-medroxyprogesterone acetate (DMPA).
Amanda Stang, Pamela Schwingl, Roberto Rivera   +2 more
doaj  

The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant. [PDF]

J Infect Dis, 2022
Tanko RF, Bunjun R, Dabee S, Jaumdally SZ, Onono M, Nair G, Palanee-Phillips T, Harryparsad R, Happel AU, Gamieldien H, Qumbelo Y, Sinkala M, Scoville CW, Heller K, Baeten JM, Bosinger SE, Burgener A, Heffron R, Jaspan HB, Passmore JAS.   +19 more
europepmc   +1 more source

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. [PDF]

Pharmacogenet Genomics, 2022
Haas DW, Mngqibisa R, Francis J, McIlleron H, Robinson JA, Kendall MA, Baker P, Mawlana S, Badal-Faesen S, Angira F, Omoz-Oarhe A, Samaneka WP, Denti P, Cohn SE, AIDS Clinical Trials Group A5338 Study Team.   +14 more
europepmc   +1 more source

A Systematic Review and Meta-Analysis of the Association Between Depot Medroxyprogesterone Acetate and Cerebral Meningioma. [PDF]

Cancers (Basel)
Reynolds LM, Arend RC, Griffin RL.
europepmc   +1 more source

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. [PDF]

Clin Pharmacol Ther, 2021
Francis J, Mngqibisa R, McIlleron H, Kendall MA, Wu X, Dooley KE, Firnhaber C, Godfrey C, Cohn SE, Denti P, A5093, A5283, A5338 study teams.   +12 more
europepmc   +1 more source

Return to fertility after subcutaneous depot medroxyprogesterone acetate: a narrative review. [PDF]

BMJ Sex Reprod Health
Osoti A, Kidula N, Mengesa LB, Kiarie JN.   +3 more
europepmc   +1 more source